Effect on cell kill of addition of multidrug resistance modifiers cyclosporin A and PSC 833 to cytotoxic agents in chronic lymphocytic leukaemia

Leukemia Research

Volumn 23, Issue 1, 1999, Pages 29-35

  Grey, Mark R ^a   Burgess, Robert ^a   Fisher, Alison ^b   Liu Yin, John A ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

CLL; Cyclosporin A; LD50; MDR; MMT; PSC 833

Indexed keywords

CYCLOSPORIN A; DAUNORUBICIN; DOXORUBICIN; FLUDARABINE; GLYCOPROTEIN P; IDARUBICIN; MITOXANTRONE; TETRAZOLIUM; VALSPODAR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CELL KILLING; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CELL SURVIVAL; CYCLOSPORINE; CYCLOSPORINS; CYTOTOXINS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; P-GLYCOPROTEIN; TUMOR CELLS, CULTURED;

EID: 0032889713     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(98)00136-2     Document Type: Article

References (37)

1. Juliano R, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovarian cell mutants. Biochim Biophys Acta 1976;455:152-62.
2. Kartner N, Riordan JR, Ling V. Cell surface P-glycoprotein is associated with multidrug resistance in mammalian cell lines. Science 1983;221:1285-92.
3. Schinkel AH, Smit JJM, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CAAM, van de Valk MA, Robanus-Maandag EC, te Riele HPJ, Berns AJM, Borst P. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994;77:491-503.
4. Baines P, Cumber P, Padua RA. Multidrug resistance in leukaemia. Baillière's Clin Haematol 1992;5(4):943-60.
5. Nooter K, Sonneveld P. Review: clinical relevance of P-glycoprotein in haematological malignancies. Leuk Res 1994;18:233-43.
6. Germann UA. P-glycoprotein - a mediator of multidrug resistance in tumour cells. Eur J Cancer 1996;32A:927-44.
7. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukaemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981;41:1967-72.
8. Twentyman PR. Cyclosporins as drug resistance modifiers. Biochem Pharmacol 1992;43:109-17.
9. Ross DD, Wooten PJ, Sridhara R, Ordonez JV, Lee EJ, Schiffer CA. Enhancement of daunorubicin accumulation, retention and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukaemia. Blood 1993;82(4):1288-99.
10. Gaveriaux C, Boesch D, Jachez B, Bollinger P, Payne T, Loor F. SDZ PSC 833, a non-immunosuppressive cyclosporin analogue, is a very potent multidrug resistance modifier. J Cell Pharmacol 1991;2:225-34.
11. Jiang XR, Kelsey SM, Wu YL, Newland AC. Circumvention of P-glycoprotein-mediated drug resistance in human leukaemia cells by non-immunosuppressive cyclosporin D analogue, SDZ PSC 833. Br J Haematol 1995;90:375-83.
12. Dighiero G, Travade P, Chevret S, Fenaux P, Chastang C, et al. B-cell chronic lymphocytic leukaemia: present status and future directions. Blood 1991;78:1901-14.
13. Michieli M, Raspadori D, Damiani D, Geromin A, Gallizia C, Michelutti A, Fanin R, Fasola G, Russo D, Tazzari P, Pileri S, Mallardi F, Baccarani M. The expression of multidrug resistance-associated glycoprotein in B-cell chronic lymphocytic leukaemia. Br J Haematol 1991;77:460-5.
14. Shustik C, Groulx N, Gros P. Analysis of multidrug resistance (MDR-1) gene expression in chronic lymphocytic leukaemia (CLL). Br J Haematol 1991;79:50-6.
15. Bosanquet AG, Bell PB, Burlton AR, Amos TA. Correlation of bcl-2 with P-glycoprotein expression in chronic lymphocytic leukaemia and other haematological neoplasms but of neither marker with ex-vivo chemosensitivity or patient survival. Leuk Lymphoma 1996;24(1-2):141-7.
16. Sparrow RL, Hall FJ, Siregar H, Van der Weyden MB. Common expression of the multidrug resistance marker P-glycoprotein in B-cell chronic lymphocytic leukaemia and correlation with in vitro drug resistance. Leuk Res 1993;17:941-7.
17. Wulf G, Kluding H, Ho AD, Doerner M, Doehner H, Manegold C, Hunstein W. Multidrug resistance phenotype in patients with chronic lymphocytic leukaemia as detected by immunofluorescence (FACS) and northern blot analysis. Leuk Res 1994;18:475-84.
18. Di Simone D, Testi R, Caracciolo F, Capochiani E, Ambrogi F, Grassi B, Petrini M. Glutathione-S-transferase activity and multidrug resistance phenotype in chronic lymphocytic leukaemia: do they have any clinical relevance? Acta Haematol 1995;80(2):103-7.
19. Wall DM, el-Osta S, Tzelepis D, Bertoncello I, Kanthardis P, Chou ST, Zalcberg JR, Parkin JD. Expression of mdr 1 and mrp in the normal B-cell homologue of B-cell chronic lymphocytic leukaemia. Br J Haematol 1997;96(4):697-707.
20. Cumber PM, Jacobs A, Hoy T, Whittaker JA, Tsuruo T, Padua RA. Increased drug accumulation ex vivo with cyclosporin in chronic lymphocytic leukaemia and its relationship to epitope masking of P-glycoprotein. Leukaemia 1991;5:1050-3.
21. Ludescher C, Hilbe W, Eisterer W, Preuss E, Hofmann J, Thaler J. Functional detection of P-glycoprotein expressing cells with flow cytometry. Wein Klin Wochenschr 1994;106(8):242-6.
22. Wood P, Burgess R, MacGregor A, Liu Yin JA. P-glycoprotein expression on acute myeloid leukaemia blast cells at diagnosis predicts response to chemotherapy and survival. Br J Haematol 1994;87:509-14.
23. Beck WT, Grogan TM, Willman CL, et al. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res 1996;56:3010-20.
24. Grey M, Borg AG, Wood P, Burgess R, Fisher A, Liu Yin JA. Effect on cell kill of addition of multidrug resistance modifiers cyclosporin A and PSC 833 to cytotoxic agents in acute myeloid leukaemia. Leuk Res 1997;21(9):867-74.
25. Van den Heuvel-Eibrink MM, van der Holt B, te Boekhorst PAW, Pieters R, Schoester M, Lowenberg B, Sonneveld P. MDR 1 expression is an independent prognostic factor for response and survival in de novo acute myeloid leukaemia. Br J Haematol 1997;99:76-83.
26. Leith CP, Chen I-M, Kopecky KJ, Applebaum FR, Head DR, Godwin JE, Weick JK, Willman CL. Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukaemia by multiparameter flow cytometry: identification of discordant MDR - /efflux + and MDR1 + /efflux - cases. Blood 1995;86:2329-42.
27. Holmes JA, Jacobs A, Carter G, Whittaker JA, Bentley DP, Padua RA. Is the MDR-1 gene relevant in chronic lymphocytic leukaemia? Leukaemia 1990;4(3):216-8.
28. Cumber PM, Jacobs A, Hoy T, Fisher J, Whittaker JA, Tsuruo T, Padua RA. Expression of the multiple drug resistance gene (mdr-1) and epitope masking in chronic lymphocytic leukaemia. Br J Haematol 1990;76:226-30.
29. Collins RJ, Verschuer LA, Harmon BV, Prentice RL, Pope JH, Kerr JFR. Spontaneous programmed death (apoptosis) of B-lymphocytic leukaemia cells following their culture in vitro. Br J Haematol 1989;71:343-50.
30. Dancescu M, Rubio-Trujillo M, Biron G, Bron D, Delespesse G, Sarfati M. Interleukin 4 protects chronic lymphocytic leukaemic B cells from death by apoptosis and upregulates Bcl-2 expression. J Exp Med 1992;176:1319-26.
31. Russo D, Marie JP, Zhou DC, Gaussat AM, Delmer A, Mainonneuve L, Ngoc LH, Baccarani M, Zittoun R. Co-expression of anionic glutathione-S-transferase (GST pi) and multidrug resistance (mdr1) genes in acute myeloid and lymphoid leukaemia. Leukaemia 1994;8:881-4.
32. Kaufman SH, Karp JE, Jones RJ, Miller CB, Schneider E, Zwelling LA, Cowan K, Wendel K, Burke P. Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukaemia. Blood 1994;83:881-4.
33. 6-alkylguanines in the nuclear DNA of human lymphocytes and leukaemic cells; analysis at single cell level. Br J Cancer 1994;69:698-705.
34. Cole SPC, Bhardwaj G, Gerlach JH, Machie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AMV, Deeley RG. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992;258:1650-4.
35. Krishnamachary N, Center MS. The MRP gene associated with a non P-glycoprotein multidrug resistance encodes a 190-kDa membrane bound glycoprotein. Cancer Res 1993;53:3658-61.
36. Scheffer GL, Wijngaard PL, Flens MJ, Izquierdo MA, Slovak ML, Pinedo HM, Meijer CJ, Clevers HC, Scheper RJ. The drug resistance-related protein LRP is the human major vault protein. Nat Med 1995;1:578-82.
37. List AF. The role of multidrug resistance and its pharmacological modulation in acute myeloid leukaemia. Leukaemia 1996;10:S36-8.